Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
USP9Y
REST API REST API
Homo sapiens
USP9Y is differentially expressed in 238 experiments: 48 organism parts: liver, kidney, ... (46 more);, 107 disease states: normal, cervical carcinoma, ... (105 more);, 65 cell types 385 cell lines 15 compound treatments and 64 other conditions.
Synonyms DFFRY
Orthologs ENSCING00000011983 (Ciona intestinalis)   usp9 (Danio rerio)   E1BWJ5_CHICK (Gallus gallus)   ENSCING00000002637 (Ciona intestinalis)   ENSCING00000016148 (Ciona intestinalis)   Usp9y (Mus musculus)   faf (Drosophila melanogaster)   usp9x (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytoplasm, BMP signaling pathway, ubiquitin thiolesterase activity, peptidase activity, spermatogenesis, transforming growth factor beta receptor signaling pathway, ubiquitin-specific protease activity, protein deubiquitination, binding, cysteine-type peptidase activity, ubiquitin-dependent protein catabolic process, co-SMAD binding
InterPro Term Peptidase_C19
UniProt Accession O00507
Gene-Disease Assocation SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2
Search EB-eye ENSG00000114374
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MTAB-25, E-GEOD-1563, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
LNCaP
3
E-GEOD-14990, E-GEOD-762, E-GEOD-14464
BT474
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MTAB-37, E-MEXP-1014
Jurkat
1
2
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
K562
1
2
E-GEOD-24147, E-GEOD-96, E-MTAB-37
379 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, E-GEOD-13987, E-MEXP-466, ... (40 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-6740
plasma cell
2
E-GEOD-6691, E-MEXP-2360
fibroblast
1
2
E-MEXP-466, E-GEOD-3920, E-GEOD-26672
M1 macrophage
1
E-GEOD-5099
Leukocytes
1
E-GEOD-21909
naive T cell
1
E-GEOD-1460
59 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-MEXP-2069, E-GEOD-16363, ... (29 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-7307
control
2
E-GEOD-16363, E-GEOD-21340
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
juvenile idiopathic arthritis subtype oligoarthritis
1
E-GEOD-13501
sarcoma
1
E-MTAB-37
101 more value(s).


Compound treatment

studied in E-GEOD-412, E-GEOD-2803, E-TABM-127, E-GEOD-6400, E-GEOD-5099, ... (11 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-2803, E-GEOD-412, E-MEXP-1958, E-GEOD-5099
control
30
1
E-GEOD-5339
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
sapphyrin PCI-2052
1
E-GEOD-6400
AMP
1
E-MEXP-2285
hydroxyurea
1
E-GEOD-6431
9 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
48
1
1
E-GEOD-21653
38
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-7967, E-TABM-125, E-GEOD-2171, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-5372, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-3325, E-TABM-147, E-GEOD-2280, E-GEOD-3013 ... (5 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-GEOD-20847, E-MTAB-108, E-MEXP-563

Genotype
studied in E-GEOD-2466, E-TABM-321, E-GEOD-18005, E-GEOD-3790, E-GEOD-17347, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, E-MEXP-2146, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-TABM-40, E-GEOD-2466, ... (48 experiments)

Infection
studied in E-MEXP-561, E-GEOD-980

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-MEXP-70

Sex
studied in E-GEOD-22097, E-MEXP-114, E-GEOD-3860, E-GEOD-20153, E-GEOD-2508, ... (44 experiments)

Stimulation
studied in E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-2748

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.453 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM